SG11201907442UA - METHODS FOR INCREASING BLOOD PLASMA 2'-DEOXYURIDINE (dUrd) AND THYMIDYLATE SYNTHASE INHIBITION - Google Patents

METHODS FOR INCREASING BLOOD PLASMA 2'-DEOXYURIDINE (dUrd) AND THYMIDYLATE SYNTHASE INHIBITION

Info

Publication number
SG11201907442UA
SG11201907442UA SG11201907442UA SG11201907442UA SG11201907442UA SG 11201907442U A SG11201907442U A SG 11201907442UA SG 11201907442U A SG11201907442U A SG 11201907442UA SG 11201907442U A SG11201907442U A SG 11201907442UA SG 11201907442U A SG11201907442U A SG 11201907442UA
Authority
SG
Singapore
Prior art keywords
international
methods
durd
increasing
gothenburg
Prior art date
Application number
SG11201907442UA
Inventor
Göran Carlsson
Bengt Gustavsson
Elisabeth Odin
Yvonne Wettergren
Anders Vedin
Original Assignee
Isofol Medical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isofol Medical Ab filed Critical Isofol Medical Ab
Publication of SG11201907442UA publication Critical patent/SG11201907442UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 23 August 2018 (23.08.2018) WIP0 I PCT onion °nolo OH 100 0010111010IIII 1111101 ow (10) International Publication Number WO 2018/150264 Al (51) International Patent Classification: A61K 39/395 (2006.01) A61K 31/519 (2006.01) A61K 45/06 (2006.01) A61K 31/555 (2006.01) A61K 31/4745 (2006.01) A61P 35/00 (2006.01) A61K 31/513 (2006.01) (21) International Application Number: PCT/IB2018/000206 (22) International Filing Date: 09 February 2018 (09.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/458,868 14 February 2017 (14.02.2017) US (71) Applicant: ISOFOL MEDICAL AB [SE/SE]; Biotech Center, Arvid Wallgrens Backe 20, SE-413 46 Gothenburg (SE). (72) Inventors: CARLSSON, Goran, U.; Vavarevagen 33, SE-433 75 Jonsered (SE). GUSTAVSSON, Bengt; Bergs- bogatan 29, SE-426 79 Vastra Frolunda (SE). ODIN, Elis- abeth; Prastgardsangen 19, SE-412 71 Gothenburg (SE). WETTERGREN, Yvonne; Gotabergsgatan 28 B, SE-411 34 Gothenburg (SE). VEDIN, Anders; Prastgardsangen 62, SE-412 71 Gothenburg (SE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (54) Title: METHODS FOR INCREASING BLOOD PLASMA 2'-DEOXYURIDINE (dUrd) AND THYMIDYLATE SYNTHASE INHIBITION FIG. 1 IWO 80 LI.V 30 6R 30 O kt) (57) : The present invention provides methods for increasing plasma dUrd levels comprising the administration of 6R-MTHF. The methods of increasing plasma dUrd increase dUrd levels compared to equimolar concentrations of LV. The present invention 0 also provides methods for increasing TS inhibition comprising the administration of 6R-MTHF. The present invention also provides \" methods for increasing TS inhibition comprising the administration of 6R-MTHF. C [Continued on next page] WO 2018/150264 Al IMEDIMOMMIONE1013110011010HINHINVOIMIE EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
SG11201907442UA 2017-02-14 2018-02-09 METHODS FOR INCREASING BLOOD PLASMA 2'-DEOXYURIDINE (dUrd) AND THYMIDYLATE SYNTHASE INHIBITION SG11201907442UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762458868P 2017-02-14 2017-02-14
PCT/IB2018/000206 WO2018150264A1 (en) 2017-02-14 2018-02-09 METHODS FOR INCREASING BLOOD PLASMA 2'-DEOXYURIDINE (dUrd) AND THYMIDYLATE SYNTHASE INHIBITION

Publications (1)

Publication Number Publication Date
SG11201907442UA true SG11201907442UA (en) 2019-09-27

Family

ID=62002152

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201907442UA SG11201907442UA (en) 2017-02-14 2018-02-09 METHODS FOR INCREASING BLOOD PLASMA 2'-DEOXYURIDINE (dUrd) AND THYMIDYLATE SYNTHASE INHIBITION

Country Status (16)

Country Link
US (3) US10292984B2 (en)
EP (2) EP3582812A1 (en)
JP (2) JP7122256B2 (en)
KR (1) KR20190112711A (en)
CN (1) CN110430896A (en)
AR (1) AR110800A1 (en)
AU (1) AU2018220861B2 (en)
BR (1) BR112019016668A2 (en)
CA (1) CA3053293C (en)
IL (1) IL268439B2 (en)
MX (1) MX2019009610A (en)
NZ (1) NZ756408A (en)
PH (1) PH12019501893A1 (en)
SG (1) SG11201907442UA (en)
TW (1) TWI803480B (en)
WO (1) WO2018150264A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018220861B2 (en) * 2017-02-14 2021-08-19 Isofol Medical Ab Methods for increasing blood plasma 2'-deoxyuridine (dUrd) and thymidylate synthase inhibition
WO2023046307A1 (en) * 2021-09-27 2023-03-30 Isofol Medical Ab [6r]-mthf in 5-fu based chemotherapy of right-sided colorectal cancer
WO2023046304A1 (en) * 2021-09-27 2023-03-30 Isofol Medical Ab [6r]-mthf in 5-fu based chemotherapy of braf- or kras-mutated colorectal cancer
WO2023046305A1 (en) * 2021-09-27 2023-03-30 Isofol Medical Ab [6r]-mthf in 5-fu based chemotherapy of left-sided colorectal cancer
CN114910579B (en) * 2022-04-13 2023-04-07 中国药科大学 Quantitative determination method for deoxyuridine in serum and application of quantitative determination method in myocardial infarction diagnosis

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376658A (en) * 1990-05-11 1994-12-27 University Of Southern California 5,10-methylene-tetrahydrofolate as a modulator of a chemotherapeutic agent
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
WO2005097086A2 (en) * 2004-04-02 2005-10-20 Adventrx Pharmaceuticals, Inc. Use of 5,10-methylene tetrahydrofolate for the treatment of cancer
KR20070019725A (en) 2004-04-02 2007-02-15 어드벤트륵스 파마슈티칼스, 인크. Use of 5,10-methylene tetrahydrofolate for the treatment of cancer
CN1942189A (en) * 2004-04-02 2007-04-04 阿德文特克斯药物有限公司 Use of 5,10-methylene tetrahydrofolate for the treatment of cancer
CA2631755A1 (en) 2005-12-02 2007-06-07 Adventrx Pharmaceuticals, Inc. Stable pharmaceutical compositions of 5,10 methylenetetrahydrofolate
AU2007299080B2 (en) * 2006-09-18 2013-04-18 Boehringer Ingelheim International Gmbh Method for treating cancer harboring EGFR mutations
WO2008109349A1 (en) 2007-03-06 2008-09-12 Adventrx Pharmaceuticals, Inc. Improved regimen for treating cancer with 5-fluorouracil, 5,10-methylenetetrahydrofolate and capecitabine
CA2738753C (en) * 2008-09-26 2018-11-06 Universite D'angers Individual 5-fluorouracile dose optimization in folfox treatment
CA2796205A1 (en) * 2010-04-15 2011-10-20 Vegenics Pty Limited Combination treatment with vegf-c antagonists
EP2617422A1 (en) * 2012-01-20 2013-07-24 Isofol Medical AB Anti-tumor activity of reduced folates like methylene-tetrahydrofolate, tetrahydrofolate or methyl-tetrahydrofolate
EP2617421A1 (en) * 2012-01-20 2013-07-24 Isofol Medical AB Tetrahydrofolates in combination with EGFR-inhibitors in the use of treating cancer
WO2018065446A1 (en) * 2016-10-05 2018-04-12 Isofol Medical Ab [6r]-mthf - an efficient folate alternative in 5-fluorouracil based chemotherapy
EP3305318A1 (en) * 2016-10-05 2018-04-11 Isofol Medical AB [6r]-5,10-methylenetetrahydrofolate in 5-fluorouracil based chemotherapy
WO2018065445A1 (en) * 2016-10-05 2018-04-12 Isofol Medical Ab [6r]-mthf multiple bolus administration in 5-fluorouracil based chemotherapy
EP3446703A1 (en) 2017-08-24 2019-02-27 Isofol Medical AB 6r]-mthf multiple bolus administration in 5-fluorouracil based chemotherapy
AU2018220861B2 (en) * 2017-02-14 2021-08-19 Isofol Medical Ab Methods for increasing blood plasma 2'-deoxyuridine (dUrd) and thymidylate synthase inhibition

Also Published As

Publication number Publication date
PH12019501893A1 (en) 2019-10-21
US11389452B2 (en) 2022-07-19
AR110800A1 (en) 2019-05-02
US20180289711A1 (en) 2018-10-11
RU2019126648A3 (en) 2021-03-16
EP3848036A2 (en) 2021-07-14
CN110430896A (en) 2019-11-08
US10639311B2 (en) 2020-05-05
MX2019009610A (en) 2020-01-14
EP3582812A1 (en) 2019-12-25
EP3848036A3 (en) 2021-08-18
US20190240224A1 (en) 2019-08-08
US10292984B2 (en) 2019-05-21
IL268439B2 (en) 2024-04-01
TWI803480B (en) 2023-06-01
CA3053293C (en) 2023-01-03
JP2021008510A (en) 2021-01-28
JP7122256B2 (en) 2022-08-19
IL268439B1 (en) 2023-12-01
JP2020505316A (en) 2020-02-20
US20200330468A1 (en) 2020-10-22
TW201832766A (en) 2018-09-16
RU2019126648A (en) 2021-03-16
BR112019016668A2 (en) 2020-04-07
IL268439A (en) 2019-09-26
AU2018220861B2 (en) 2021-08-19
NZ756408A (en) 2024-01-26
WO2018150264A1 (en) 2018-08-23
CA3053293A1 (en) 2018-08-23
AU2018220861A1 (en) 2019-09-05
KR20190112711A (en) 2019-10-07

Similar Documents

Publication Publication Date Title
SG11201907442UA (en) METHODS FOR INCREASING BLOOD PLASMA 2'-DEOXYURIDINE (dUrd) AND THYMIDYLATE SYNTHASE INHIBITION
SG11201808990QA (en) Compositions for topical application of compounds
SG11201811432WA (en) Rna for cancer therapy
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201909949XA (en) Targeted immunotolerance
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201808799SA (en) Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors
SG11201804443UA (en) Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201900349VA (en) Somatostatin modulators and uses thereof
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201807913XA (en) Stabilized soluble pre-fusion rsv f proteins
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201906853QA (en) Anti-rsv monoclonal antibody formulation
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201809594WA (en) Nicotine particles and compositions
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201808713YA (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier